forced degradation: what? why? how? - cbi | powering … b(1).pdf · · 2015-12-02forced...
TRANSCRIPT
![Page 1: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/1.jpg)
Forced Degradation:What? Why? How?
Thomas R. SharpFreeThink Technologies, Inc.
Groton, Connecticut([email protected])
1www.freethinktech.com
![Page 2: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/2.jpg)
What?
• buzzwords
– forced degradation
– stability testing
– stress testing
• interconnected, but not equivalent or interchangeable
www.freethinktech.com 2
![Page 3: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/3.jpg)
What?
• nothing is infinitely stable – entropy!
• determining “mtbf” (mean time before failure)
– electronics industry: how soon can you expect your hard disk to crash, your monitor to go dark?
– automobiles: how soon will the exhaust system or the fenders rust away?
– pharma: when should I throw that old bottle of aspirin away?
3www.freethinktech.com
![Page 4: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/4.jpg)
teacups
• manufacturing teacups?
• nobody wants to buy a faulty teacup!
• nobody wants it to “fail” soon after purchase
• why test?
– correct manufacturing faults
– set life expectancies
– demonstrate robustness
www.freethinktech.com 4
![Page 5: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/5.jpg)
teacups
• failure modes
– different failure modes
– but all have failed!
www.freethinktech.com 5
![Page 6: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/6.jpg)
teacups
• how to test?
• which tool?
• too much?
www.freethinktech.com 6
![Page 7: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/7.jpg)
How it all fits together
www.freethinktech.com 7
degradationmechanisms
degradantidentification
formulationdevelopment
packaging
![Page 8: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/8.jpg)
www.freethinktech.com 8
![Page 9: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/9.jpg)
Current Practices
• ICH guidelines
– degradant = compound resulting from chemical change caused over time by light, temperature, pH, humidity, excipients, etc.
– where the guidelines fall short
• not big on specific details
• subject to individual & regulatory agency interpretation and discretion
• not uniformly interpreted across all countries/marketplaces
freethinktech.com 9
![Page 10: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/10.jpg)
Why?
• provides materials used to develop stability-indicating assays
– method that actually differentiates good from bad
– forced degradation products demonstrate that one has a stability-indicating method
• demonstrates product robustness
• set rational shelf life expectations & expiry dates
• safety considerations (toxics or genotoxics?)
• because it’s required!10www.freethinktech.com
![Page 11: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/11.jpg)
How?
• identify condition(s) that induce “failure”
– pH, temperature, humidity, light, time, etc.
• choose rational conditions that induce failure
– how much is enough, how much is too much?
– “little hammer or BIG hammer”
– not too much, not too little
• ~10% to 20% loss of drug substance
• don’t over-degrade and chase unnecessary degradants
www.freethinktech.com 11
![Page 12: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/12.jpg)
How it all fits together
www.freethinktech.com 12
degradationmechanisms
degradantidentification
formulationdevelopment
packaging
![Page 13: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/13.jpg)
identifying degradants
• how much “identification” is enough?
– phase-dependent
• early phase: a little bit can be enough
• late phase: the whole enchilada!
• presumptive vs. confirmatory identification
– (relative) retention times, retention indices
– LC-UV vs. LC-MS
– NMR characterization
– synthesis (the final word!) & comparison
freethinktech.com 13
![Page 14: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/14.jpg)
computer-assisted identification?
• Two fundamental approaches
– logic-oriented
• ab initio computation – quantum chemistry
• expert systems– CAMEO, Delphi, Zeneth®
– information-oriented
• databases, algorithms, statistics, examples– Pharma D3® drug degradation database
• 393 drugs, >1200 degradants, literature references
• http://d3.arxspan.com/
– Marvin (ChemAxon), ACD Labs, XLogP, etc.
www.freethinktech.com 14
![Page 15: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/15.jpg)
ab inito – what to compute?
• C-H bond dissociation energies to indicate reactive sites
• some energies change with protonation
www.freethinktech.com 15
• Thomas R. Sharp (2011). Calculated carbon-hydrogen bond dissociation enthalpies for predicting oxidative susceptibility of drugsubstance molecules. International Journal of Pharmaceutics 418,304-317.
• Thomas Andersson, Anders Broo, Emma Evertsson (2014). Prediction of drug candidates’ sensitivity toward autoxidation: Computational estimation of C-H dissociation energies of carbon-centered radicals. Journal of Pharmaceutical Sciences 103,1949-1955.
![Page 16: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/16.jpg)
in silico predictions
• Zeneth® – logic-based
– knowledge from the literature
– perception of structures & patterns
– prediction based on chemical “rules”
– interactions of drugs with themselves & with excipients
www.freethinktech.com 16
• Alexis D.C. Parenty, William G. Button, Martin A. Ott (2013). An expert system to predict the forced degradation of organic molecules. Molecular Pharmaceutics 10,2962-2974.
• Mark H. Kleinman, Steven W. Baertschi, Karen M. Alsante, Darren L. Reid, Mark D. Mowery, Roman Shimanovich, Christopher Foti, William K. Smith, Dan W. Reynolds, Marcela Nefliu, Martin A. Ott (2014). In silico prediction of pharmaceutical degradation pathays: A benchmarking study. Molecular Pharmaceutics 11,4179-4188.
![Page 17: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/17.jpg)
www.freethinktech.com 17
Steven W. Baertschi, Karen M. Alsante, Dinos P. Santafianos (2011). Chapter 3. Stress testing: The chemistry of drug degradation. in S.W. Baertschi, K.M. Alsante, R.A. Reed, Pharmaceutical Stress Testing: Predicting drug degradation (2nd Ed). London: InformaHealthcare. Pp. 49-141.
insights from Pharma D3 database• 0: isomerization, etc.
• -2: dehydrogenation
• +1: amide to acid
• ±16: add/subractoxygen
• ±18: add/subtract water
![Page 18: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/18.jpg)
acid/base
• aqueous 0.1 N acid or base
• organic co-solvents acceptable if necessary
– choose to avoid solvent side reactions
• room temperature & in the dark
– to separate acid/base lability from temperature-or light-induced effects
• timecourse – 24 hours, up to 1 week
• what about intermediate pHs?
www.freethinktech.com 18
![Page 19: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/19.jpg)
bupropion
• Welbutrin® – numerous therapeutic indications
• solution-stable below pH 5
• several degradants between pH 5 and pH 10
• mcba above pH 10
• OH− catalyzed degradation of free base
www.freethinktech.com 19
Cl
O
HN
Cl
O
OHCl
O
O
Cl
O OH
Cl
HO
Obupropion
m-chlorobenzoic acid
propanedione
(degradant E)
hydroxypropanone 1
(degradant C)
hydroxypropanone 2
(degradant F)
Paul M. O’Byrne, Robert Williams, John J. Walsh, John F. Gilmer (2010). The aqueous stability of bupropion. Journal of Pharmaceutical and Biomedical Analysis 53,376-381.
![Page 20: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/20.jpg)
when we want it to degrade!
• dabigatran etexilate (prodrug, Pradaxa®)
– anticoagulant
• mimicking
– stomach, pH 1.5
– blood, pH 7.4
www.freethinktech.com 20
N
N
NH
HN
HN
N
O
O
O
N
O
O
![Page 21: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/21.jpg)
thermal and humidity challenge
• humidity control using colligative properties of saturated salt solutions
• monitors to record actual temp/humidity exposure (don’t just assume)
• Arrhenius chemistry
– elevated temp/humidity speeds reactions
www.freethinktech.com 21
• Lewis Greenspan (1977). Humidity fixed points of binary saturated aqueous solutions. Journal of Research of the National Bureau of Standards – A. Physics and Chemistry 81A(1),89-96.
• Paul W. Winston (1960). Saturated solutions for the control of humidity in biological research. Ecology 41(1),232-237.• F.E.M. O’Brien (1948). The control of humidity by saturated salt solutions. Journal of Scientific Instruments 25,73-76.
![Page 22: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/22.jpg)
Arrhenius chemistry
www.freethinktech.com 22
Gary Scrivens (2015). Personal communications
• moisture-modified Arrhenius equation
ln k = ln A – Ea/RT + B(RH)
![Page 23: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/23.jpg)
Arrhenius chemistry
• moisture-modified Arrhenius equation
ln k = ln A – Ea/RT + B(RH)
• moisture “B” term important for solid state
– hygroscopic drug, excipients (or both)
– deliquescence
• Ea – temp sensitivity
• “A” term – contact
www.freethinktech.com 23
![Page 24: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/24.jpg)
• a very complex problem
• multiple modes and mechanisms
– hydrogen abstraction
• autoxidation
• radical-initiated
– oxygen addition
• peroxide-mediated
– electron loss
www.freethinktech.com 24
oxidation
S.W. Baertschi (2015). Personal communications
![Page 25: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/25.jpg)
oxidation
www.freethinktech.com 25
S.W. Baertschi (2015). Personal communications
![Page 26: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/26.jpg)
oxidation
• oxygen exposure
– H2O2 (3%) historically used, but not predictive of molecular oxygen reactions
– pressurized oxygen – not very stability-indicating?
• diazene free radical initiators
– AIBN, AAPH, etc.
– organic co-solvents (ACN preferred over MeOH)
– elevated temperatures
www.freethinktech.com 26
![Page 27: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/27.jpg)
photostability
• standard portions of EM spectrum• visible – 400 nm to 800 nm
• UV-A – 320 nm to 400 nm
• UV-B – 290 nm to 320 nm
• UV-C – 200 nm to 290 nm
– Option 1: D65 (outdoor daylight) and ID65 (indoor indirect daylight) ISO 10977(1993) standards
– Option 2: both cool-white (similar to above) and near-UV with a range of 320 nm to 400 nm (UV-A)
freethinktech.com 27
![Page 28: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/28.jpg)
How?
• other “inadvertent” conditions?
– drug salt forms – drug-counterion interactions?
– drug-drug interactions
• multiple active ingredients
• degradants quantitated initially (area%) to the lowest active ingredient
– drug-excipient interactions?
– excipient-excipient interactions
www.freethinktech.com 28
![Page 29: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/29.jpg)
mechanical processing
• milling adds a lot of “energy” to the drug substance
• blending with excipients
• annealing
• sonication
• etc.
www.freethinktech.com 29
![Page 30: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/30.jpg)
sample preparation is important!
• sonication generates radicals
– can induce peroxide oxidation
– inadvertent forced degradation
www.freethinktech.com 30
• Christian Petrier, Andre Jeunet, Jean-Louis Luche, Gilbert Reverdy (1992). Unexpected frequency effects on the rate of oxidative processes induced by ultrasound. Journal of the American Chemical Society 114(8),3148-3150.
• Steven W. Baertschi, Pat Jansen et al. (2006). IIR Forced Degradation Conference, Short Hills, N.J.• Steven W. Baertschi (2015). Personal communications.
![Page 31: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/31.jpg)
Maillard reaction
• early lore suggests only primary amines react
• fluoxetine (secondary amine) and lactose
www.freethinktech.com 31
David D. Wirth, Steven W. Baertschi, Ross A. Johnson, Steven R. Maple, Marybeth S. Miller, Diana K. Hallenbeck, Stephen M. Gregg (1998). Maillard reaction of lactose and fluoxetine hydrochloride, a secondary amine. Journal of Pharmaceutical Sciences 87(1),31-39.
OHN
F
F
F
O
OH
OH
OH
HO
OH
OH
HO
N O
F
F
FO
OH
OH
OH
HO
OH
OH
OH
HO
H2O
H2O
![Page 32: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/32.jpg)
cetirizine (Zyrtec®)
• an aggressive carboxylic acid (pKa 3.6)
• forms esters, amides with
– other drug substances in the formulation
– amides/alcohols of excipients/other actives
• glycerol ester
• pseudoephedrine ester/amide
• poly(ethylene glycol) ester
• β-cyclodextrin esters
www.freethinktech.com 32
Cl O
OH
O
N
N
![Page 33: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/33.jpg)
cetirizine PEG esters
• PEG 300 in the formulation
• “aggressive” ester formation
www.freethinktech.com 33
Cl O
O
O
N
N
OH
cetirizine PEG esters
C2 1H2 5N2O3Cl[C2H4O]n
r.m.m. 388 + [44]n
n formula r.m.m.
6 C21H24N2O2Cl(OC2H4)6OH 652.3
7 C21H24N2O2Cl(OC2H4)7OH 696.3
![Page 34: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/34.jpg)
trovafloxacin & excipients
• amide formation with fatty acids in magnesium stearate excipient (tablet press lubricant)
www.freethinktech.com 34
F
F
F
O
OH
O
N
NH
N N
H
HO
n
![Page 35: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/35.jpg)
azithromycin single-dose sachet
• high-temperature annealing step
• ester formation with fatty acids (“magnesium stearate”) in formulation
www.freethinktech.com 35
O
O
OH
O
OO
O
OH
OH
HO
OH
O
N N
HO
HO
HO
O
O
O
![Page 36: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/36.jpg)
www.freethinktech.com 36
Steven W. Baertschi, Karen M. Alsante, Dinos P. Santafianos (2011). Chapter 3. Stress testing: The chemistry of drug degradation. in S.W. Baertschi, K.M. Alsante, R.A. Reed, Pharmaceutical Stress Testing: Predicting drug degradation (2nd Ed). London: Informa Healthcare. Pp. 49-141.
insights from Pharma D3 database
• an unusual M+58 adduct
• only 1 in Pharma D3
database
![Page 37: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/37.jpg)
www.freethinktech.com 37
M+58 adduct
• sodium starch glycolate (Explotab®, Ac-Di-Sol®)
– tablet disintigrant – GRAS
– starch carboxymethylated with Na chloroacetate
P.M. Young (2009). Sodium starch glycolate. in R.C. Rowe, P.J. Sheskey, M.E. Quinn, Handbook of Pharmaceutical Excipients (6th Ed). London: Pharmaceutical Press. Pp. 663-666.
![Page 38: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/38.jpg)
M+58 adduct
• varenicline (Chantix®) tablet formulation containing sodium starch glycolate
• residual chloroacetic acid in the excipient reacts with drug substance
www.freethinktech.com 38
D. Santafianos (personal communications). varenicline-excipient interaction
Cl
OH
O
HCl
![Page 39: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/39.jpg)
excipient-excipient interactions
• tromethamine & benzaldehyde form a Schiff base in vehicle, appear in chromatogram
– tromethamine, for pH control
– benzaldehyde, from cherry flavor
– reversible – goes away on incubation
www.freethinktech.com 39
![Page 40: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/40.jpg)
solid-state vs. in-solution stability
• pick the right indicator degradant!
• not always the same indicator degradant(s)
– in solid state
– does not accumulate in solution-degraded drug samples. Reactive – goes on to other degradants (?)
www.freethinktech.com 40
N
OH
R
N
O
R
![Page 41: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/41.jpg)
additional stability criteria
• does not have to be a degradant appearing in a chromatogram
• define a stability test and an objective failure criterion
– color/appearance – tristimulus measurement
– dissolution – the Q point
freethinktech.com 41
![Page 42: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/42.jpg)
additional stability criteria
• dissolution
– attempts to correlate in vitro dissolution performance with in vivo oral drug performance & bioavailability
– establish specifications for batch-to-batch quality assurance
– becomes the official compendial specification for all subsequent immediate release products with the same active ingredient
freethinktech.com 42
![Page 43: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/43.jpg)
additional stability criteria
• dissolution
– Q point
• specified % dissolution at a specified time
• the quantitative endpoint to measure “failure”
• becomes compendial specification on FDA registration of the drug/formulation
• often a very conservative specification
freethinktech.com 43
![Page 44: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/44.jpg)
0.0
20.0
40.0
60.0
80.0
100.0
0 5 10 15 30 45
% D
isso
luti
on
Time, minutes
additional stability criteria
• dissolution –10 mg tablet
– compendialQ = 85% @ 15 minutes
– conservative
freethinktech.com 44
![Page 45: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/45.jpg)
0.0
20.0
40.0
60.0
80.0
100.0
0 5 10 15 30 45
% D
isso
luti
on
Time, minutes
Control
60C/66%RH D21
60C/66%RH D24
60C/75%RH D6
60C/75%RH D8
60C/75%RH D14
60C/51%RH D10
60C/66%RH D36
additional stability criteria
• dissolution –10 mg tablet
– clear changes with stress
– but many still pass compendialrequirement
freethinktech.com 45
![Page 46: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/46.jpg)
additional stability criteria
• appearance/color
– expert evaluator – subjective, dependent on the training of the individual
– tristimulus testing – a quantitative color endpoint
– total reflectance visible spectroscopy
– International Commission on Illumination
• CIE x,y,z scale
• CIE L*a*b* scale
• Hunter L,a,b scale
freethinktech.com 46
• CIE - Commission Internationale de l'Eclairage
![Page 47: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/47.jpg)
• quantitative measure of appearance failure
– tristimulus L,a,b measurements on caplets deemed to fail appearance testing, establishing a quantitative “failure” measurement
– stability challenge caplets under accelerated time, temperature, humidity conditions
– measure L,a,b
www.freethinktech.com 47
additional stability criteria
![Page 48: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/48.jpg)
• appearance/color
– use one (or more) of tristimulus parameters to model stability, predict “failure”
– use in decision(s) to modify formulation, adjust packaging, etc.
• change excipients
• adapt/change packaging
• film-coat
www.freethinktech.com 48
additional stability criteria
![Page 49: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/49.jpg)
forced degradation of biologics?
– what is the stress?
– what are the quantifiable endpoints?
– no problem with chemical stability
• covalent bond breakage (peptide or disulfide)
• oxidation of residue(s)
• loss of prosthetic group, post-translational modifications
– what about protein conformation?
• active vs. denatured forms?
• correctly folded?
www.freethinktech.com 49
![Page 50: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/50.jpg)
how it all fits together
www.freethinktech.com 50
degradationmechanisms
degradantidentification
formulationdevelopment
packaging
![Page 51: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/51.jpg)
www.freethinktech.com 51
• Steven W. Baertschi, Karen M. Alsante, Robert A. Reed (Eds.)
– 2nd Edition
– Informa Healthcare
– ISBN 978-1-4398-0179-6
![Page 52: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/52.jpg)
References
General references
• Satinder Ahuja, Stephen Scypinski (Eds.) (2001). Handbook of Modern Pharmaceutical Analysis (1st Ed). New York: Academic Press. (ISBN 0-12-045555-2)
• Satinder Ahuja, Stephen Scypinski (Eds.) (2011). Handbook of Modern Pharmaceutical Analysis (2nd Ed). New York: Academic Press. (ISBN 978-0123756800)
• Steven W. Baertschi (Ed.) (2005). Pharmaceutical Stress Testing: Predicting Drug Degradation (1st Ed.). Boca Raton, FL: Taylor & Francis. (ISBN 978-0-8247-4021-4).
• Steven W. Baertschi, Karen M. Alsante, Robert A. Reed (Eds.) (2011). Pharmaceutical Stress Testing: Predicting Drug Degradation (2nd Ed.). New York, N.Y.: Informa Healthcare. (ISBN 978-1439801796)
• Satinder Ahuja, Karen M. Alsante (Eds.) (2003). Handbook of Isolation and Characterization of Impurities in Pharmaceuticals. New York: Academic Press. (ISBN 0-12-044982-X)
freethinktech.com 52
![Page 53: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/53.jpg)
References
Forced degradation
• Karen M. Alsante, Robert C. Friedmann, Todd D. Hatajik, Linda L. Lohr, Thomas R. Sharp, Kimberly D. Snyder, Edward J. Szczesny (2001). Degradation and impurity analysis for pharmaceutical drug candidates. in Satinder Ahuja, Stephen Scypinski (Eds.) (2001). Handbook of Modern Pharmaceutical Analysis (1st Ed). Pp. 85-172. New York: Academic Press. (ISBN 0-12-045555-2).
• Karen M. Alsante, Steven W. Baertschi, Michael Coutant, Brian L. Marquez, Thomas R. Sharp, Todd C. Zelesky (2011). Chapter 3: Degradation and Impurity Analysis for Pharmaceutical Drug Candidates. in S. Ahuja & S. Scypinski (Eds.) Handbook of Modern Pharmaceutical Analysis (2nd Ed). Pp. 59-169. (ISBN 978-0123756800).
freethinktech.com 53
![Page 54: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/54.jpg)
References
www.freethinktech.com 54
Oxidation
• E.T Denisov, T.G. Denisova, T.S. Pokidova (2003). Handbook of Free Radical Initiators. Hoboken, N.J.: Wiley Intersciences. 67 pp.
• Seema Betigeri, Ajit Thakur, Krishnaswam Raghavan (2005). Use of 2,2’-azobis(2-amidinopropane) dihydrochloride as a reagent tool for evaluation of oxidative stability of drugs. Pharmaceutical Research 22(2),310-317. (doi 10.1007/s11095-004-1199-x)
• Eric D. Nelson, Paul A. Harmon, Renee C. Szymanik, Martin G. Teresk, Randal A. Seburg, Robert A. Reed (2006). Evaluation of solution oxygenation requirements for azonitrile-based oxidative forced degradation studies of pharmaceutical compounds. Journal of Pharmaceutical Sciences 95(7),1527-1539. (doi 10.1002/jps.20626)
![Page 55: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/55.jpg)
References
Photodegradation
• Satomi Onoue, Naoko Igarashi, Shizuo Yamada, Yoshiko Tsuda (2008). High-throughput reactive oxygen species (ROS) assay: an enabling technology for screening the phototoxic potential of pharmaceutical substances. Journal of Pharmaceutical & Biomedical Analysis46,187-193. doi 10.1016/j.jpba.2007.09.003
• Satomi Onoue, Yoshiki Seto, Graham Gandy, Shizuo Yamada (2009). Drug-induced phototoxicity; An early in vitro identification of phototoxic potential of new drug entities in drug discovery and development. Current Drug Safety 4,123-136.
• Yoshiki Seto, Kazuhiro Hosoi, Hironori Takagi, Kazuichi Nakamura, Hajime Kojima, ShizuoYamada, Satomi Onoue (2012). Exploratory and regulatory assessments on photosafety of new drug entities. Current Drug Safety 7,140-148.
• Brian Henry, Christopher Foti, Karen Alsante (2009). Can light absorption and photostabilitydata be used to assess the photosafety risks in patients for a new drug molecule? Journal of Photochemistry and Photobiology B: Biology 96,57-62. doi10.1016/j.jphotobiol.2009.04.005
freethinktech.com 55
![Page 56: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/56.jpg)
References
Identification of impurities °radants
• Karen M. Alsante, Todd D. Hatajik, Linda L. Lohr, Dinos Santafianos, Thomas R. Sharp (2003). Chapter 14: Solving impurity/degradadation problems: Case studies. in S. Ahuja & K.M. Alsante (Eds.), Handbook of Isolation and Characterization of Impurities in Pharmaceuticals.New York: Academic Press. Pp. 361-400. (ISBN 0-12-044982-X).
• Linda L. Lohr, Andrew J. Jensen, Thomas R. Sharp (2003). Chapter 12: NMR Characterization of Process Related Impurities and Degradation Products from Pharmaceutical Drug Candidates. in S. Ahuja & K.M. Alsante (Eds.), Handbook of Isolation and Characterization of Impurities in Pharmaceuticals. New York: Academic Press. Pp. 301-340. (ISBN 0-12-044982-X).
• Karen M. Alsante, Todd D. Hatajik, Linda L. Lohr, Thomas R. Sharp (2001). Isolation and Identification of Process Related Impurities and Degradation Products from Pharmaceutical Drug Candidates. Part I. American Pharmaceutical Review 4(1),70-78.
freethinktech.com 56
![Page 57: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/57.jpg)
References
Identification of impurities
• Linda L. Lohr, Thomas R. Sharp, Karen M. Alsante, Todd D. Hatajik (2001). Isolation and Identification of Process Related Impurities and Degradation Products from Pharmaceutical Drug Candidates. Part II: The Roles of NMR and Mass Spectrometry. American Pharmaceutical Review 4(3),104-113.
• Thomas R. Sharp (2006). Impurity Identification in Pharmaceuticals: An integrated approach and examples of how well it works! (Part 1). American Pharmaceutical Review 9(3),100-105.
• Thomas R. Sharp (2006). Impurity Identification in Pharmaceuticals: An integrated approach and examples of how well it works! (Part 2). American Pharmaceutical Review 9(7),84-91.
• Thomas R. Sharp, Brian L. Marquez (2006). Chapter 19: Combined chromatography-spectroscopy techniques: GC-MS, LC-MS and LC-NMR. In S. Ahuja and N. Jesperson (eds.), Comprehensive Analytical Chemistry, Vol. 47: Modern Instrumental Analysis. Amsterdam: Elsevier. Pp. 691-754. (ISBN 0-444-52259-X).
• Thomas R. Sharp , Todd C. Zelesky , Mark T. Zell (2013). Impurity Identification in Pharmaceuticals. In J. Swarbrick (Ed), Encyclopedia of Pharmaceutical Science and Technology (4th Ed.). New York: Taylor and Francis. Pp.1914-1940.
freethinktech.com 57
![Page 58: Forced Degradation: What? Why? How? - CBI | Powering … B(1).pdf · · 2015-12-02Forced Degradation: What? Why? How? Thomas R. Sharp ... Dinos P. Santafianos (2011). Chapter 3](https://reader031.vdocument.in/reader031/viewer/2022020412/5af322757f8b9ac2469190bf/html5/thumbnails/58.jpg)
References
Specific studies of impurities/degradants
• Anthony M. Campeta, Franco Lombardo, Thomas R. Sharp, George J. Horan, Diane M. Rescek(1999). Identification of Photodegradants of Droloxifene by a Combined LC-MS, NMR Spectroscopy and Computational Chemistry Approach. Journal of Physical Organic Chemistry 12,881-9. doi: 10.1002/(SICI)1099-1395(199912)12
• Karen M. Alsante Peter Boutros, Michel A. Couturier, Robert C. Friedmann, James W. Harwood, George J. Horan, Andrew J. Jensen, Oscar Q. Liu, Linda L. Lohr, Ronald Morris, Jeffrey W. Raggon, George L. Reid, Dinos P. Santafianos, Thomas R. Sharp, John L. Tucker, Glenn E. Wilcox (2004). Pharmaceutical impurity identification: A case study using a multidisciplinary approach. Journal of Pharmaceutical Sciences 93,2296-2309. doi: 10.1002/jps.20120
• Andrew Blanchard, Carlos Lee, Beverly Nickerson, Linda L. Lohr, Andrew J. Jensen, Karen M. Alsante, Thomas R. Sharp, Dinos P. Santafianos, Ronald Morris, Kimberly D. Snyder (2004). Identification of low-level degradants from low dose tablets. Journal of Pharmaceutical and Biomedical Analysis 36,265-75. doi: 10.1016/j.jpba.2004.05.012
freethinktech.com 58